Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jan;45(1):e16204.
doi: 10.1111/liv.16204.

Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients

Ana Virseda-Berdices  1   2 , Rubén Martín-Escolano  1   2 , Juan Berenguer  2   3   4 , Juan González-García  2   5   6 , Oscar Brochado-Kith  1   2 , David Rojo  7 , Cristina Díez  2   4   5 , Víctor Hontañon  2   5   6 , Leire Pérez-Latorre  2   3   4 , Luis Ibañez-Samaniego  8 , Elba Llop-Herrera  9 , Antonio Olveira  10 , Amanda Fernández-Rodríguez  1   2 , Coral Barbas  7 , Salvador Resino  1   2 , María Ángeles Jiménez-Sousa  1   2 ; ESCORIAL Study Group
Collaborators, Affiliations
Multicenter Study

Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients

Ana Virseda-Berdices et al. Liver Int. 2025 Jan.

Abstract

Background and aims: In response to direct-acting antivirals (DAAs) therapy, patients who experience a decrease in hepatic venous pressure gradient (HVPG) considerably reduce liver complications and have increased survival. This study aimed to assess the metabolomic changes associated with the changes in HVPG from the start of DAA therapy until 48 weeks after effective DAA therapy in patients with advanced HCV-related cirrhosis.

Methods: We carried out a multicenter longitudinal study in 31 patients with advanced hepatitis C virus (HCV)-related cirrhosis. We performed a non-targeted metabolomic analysis using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry, as well as analysis of inflammation-related biomarkers using Luminex technology. The statistical analysis was performed by Generalised Linear Mixed-effects Models (GLMM), correcting for multiple testing.

Results: We found that increases of 2,3-butanediol (AMR = 1.15; q-value = 0.023) and taurocholic acid (AMR = 1.06; q-value < 0.001) were significantly associated with increases in HVPG and inflammatory biomarker levels from before DAA therapy to one year after completion of successful HCV treatment.

Conclusions: These metabolites have a potential role as indicators of portal hypertension evolution.

Keywords: HCV; HIV; HVPG; cirrhosis; metabolomics.

PubMed Disclaimer

References

    1. P. Gines, A. Krag, J. G. Abraldes, E. Sola, N. Fabrellas, and P. S. Kamath, “Liver Cirrhosis,” Lancet 398, no. 10308 (2021): 1359–1376.
    1. K. T. Suk, “Hepatic Venous Pressure Gradient: Clinical Use in Chronic Liver Disease,” Clinical and Molecular Hepatology 20, no. 1 (2014): 6–14.
    1. G. Garcia‐Tsao, S. Friedman, J. Iredale, and M. Pinzani, “Now There Are Many (Stages) Where Before There Was One: In Search of a Pathophysiological Classification of Cirrhosis,” Hepatology 51, no. 4 (2010): 1445–1449.
    1. V. Calvaruso and A. Craxi, “Hepatic Benefits of HCV Cure,” Journal of Hepatology 73, no. 6 (2020): 1548–1556.
    1. S. Lens, E. Alvarado‐Tapias, Z. Marino, et al., “Effects of all‐Oral Anti‐Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus‐Associated Cirrhosis,” Gastroenterology 153, no. 5 (2017): 1273–1283 e1.

Publication types

LinkOut - more resources